As previously reported, Craig-Hallum initiated coverage of Immunome (IMNM) with a Buy rating and $26 price target Heading into varegacestat’s Phase 3 topline data in desmoid tumors due in the second half and IM-1021’s Phase 1 go/no-go proof of concept data in hematological and solid tumors late in the year or in early 2026, the firm believes these catalysts “skew risk/reward to the upside” and sees an attractive entry point. Shares could trade up 45% or more in the firm’s bull cases, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome initiated with a Buy at Craig-Hallum
- Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment
- Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls
- Immunome initiated with an Outperform at Evercore ISI
- Immunome’s Promising Pipeline and Financial Stability Justify Buy Rating